^
Association details:
| Biomarker: | MLH1 V384D |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combination of EGFR-TKIs with Chemotherapy versus EGFR-TKIs alone in EGFR-Mutant Advanced NSCLC with Concomitant Genetic Alterations
Published date:
01/12/2021
Excerpt:
EGFR-TKI can be selected as one of gefitinib, erlotinib and icotinib.In sensitive EGFR-mutant NSCLC, the addition of pemetrexed to EGFR-TKIs results in significantly prolonged PFS in patients with concomitant alterations in MLH1 V384...
Secondary therapy:
pemetrexed
